1. Home
  2. VERA vs DKL Comparison

VERA vs DKL Comparison

Compare VERA & DKL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vera Therapeutics Inc.

VERA

Vera Therapeutics Inc.

HOLD

Current Price

$46.84

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

DKL

Delek Logistics Partners

HOLD

Current Price

$47.69

Market Cap

2.4B

Sector

Energy

ML Signal

HOLD

Company Overview

Basic Information
Metric
VERA
DKL
Founded
2016
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Natural Gas Distribution
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
2.4B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
VERA
DKL
Price
$46.84
$47.69
Analyst Decision
Strong Buy
Buy
Analyst Count
11
2
Target Price
$76.60
$45.50
AVG Volume (30 Days)
1.5M
50.6K
Earning Date
02-25-2026
02-24-2026
Dividend Yield
N/A
9.34%
EPS Growth
N/A
9.17
EPS
N/A
3.09
Revenue
N/A
$967,420,000.00
Revenue This Year
N/A
$11.84
Revenue Next Year
N/A
$10.55
P/E Ratio
N/A
$15.52
Revenue Growth
N/A
N/A
52 Week Low
$18.53
$34.59
52 Week High
$56.05
$48.00

Technical Indicators

Market Signals
Indicator
VERA
DKL
Relative Strength Index (RSI) 53.97 64.62
Support Level $47.22 $44.60
Resistance Level $56.05 $45.50
Average True Range (ATR) 2.35 1.04
MACD -1.00 0.24
Stochastic Oscillator 9.63 95.58

Price Performance

Historical Comparison
VERA
DKL

About VERA Vera Therapeutics Inc.

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

About DKL Delek Logistics Partners

Delek Logistics Partners LP owns and operates logistics and marketing assets for crude oil and intermediate and refined products. The company's segment includes gathering and processing; wholesale marketing and terminalling; storage and transportation and investment in pipeline joint ventures. It generates maximum revenue from the wholesale marketing and terminalling segment, which provides marketing services for the refined products output of the Delek Holdings' refineries, engages in wholesale activity at its terminals and terminals owned by third parties, whereby it purchases light product for sale and exchange to third parties, and provides terminalling services at its refined products terminals to independent third parties and Delek Holdings.

Share on Social Networks: